氯化氢 | 109103-97-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 中文名称: 氯化氢
• 英文名称: 2-bromo-1-(dibenzo[b,d]furan-2-yl)ethan-1-one
• 英文别名: 2-bromo-1-dibenzofuran-2-yl-ethanone；2-Brom-1-dibenzofuran-2-yl-aethanon；2-Bromo-1-dibenzo[b,d]furan-2-ylethanone；2-bromo-1-dibenzofuran-2-ylethanone
• CAS: 109103-97-1
• 化学式: C₁₄H₉BrO₂
• 分子量: 289.128
• InChiKey: RDWCRZMXSYYAPF-UHFFFAOYSA-N

物化性质

• 密度：
  1.561

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2806100000

反应信息

• 作为反应物：
  描述：

  氯化氢 在 乙醚 、 铂 作用下， 生成 1-dibenzofuran-2-yl-2-piperidino-ethanol
  参考文献：
  名称：

  Amino Alcohols Derived from Dibenzofuran¹

  摘要：

  DOI：

  10.1021/ja01314a045
• 作为产物：
  描述：

  1-(2-二苯并呋喃)乙酮 在 溴 、 溶剂黄146 作用下， 生成 氯化氢
  参考文献：
  名称：

  Buu-Hoi et al., Journal of the Chemical Society, 1957, p. 2593,2596

  摘要：

  DOI：

文献信息

• Compounds and compositons for treating C1s-mediated diseases and conditions
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20020037915A1

  公开（公告）日：2002-03-28

  Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I 1 or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R 1 , R 2 , R 3 , R 4 , X, Y and Z are defined in the specification.

  揭示了一种治疗急性或慢性疾病症状的方法，该疾病是由补体级联的经典途径介导的，包括向需要此类治疗的哺乳动物施用化合物I的治疗有效量或其溶剂化合物、水合物或药用可接受盐；其中规范中定义了R1、R2、R3、R4、X、Y和Z。
• [EN] 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS<br/>[FR] DERIVES DE 1-(2H-PYRAZOL-3-YL)-3-{4-`1-(BENZOYL)-PIPERIDIN-4-YLMETHYL!-PHENYL}-UREE ET COMPOSES ASSOCIES UTILISES COMME INHIBITEURS DE LA KINASE P38 ET/OU COMME INHIBITEURS DU FACTEUR DE NECROSE TUMORALE (TNF) DANS LE TRAITEMENT DES INFLAMMATIONS
  申请人：AVENTIS PHARMA INC

  公开号：WO2004100946A1

  公开（公告）日：2004-11-25

  The present invention provides compounds of Formula (I) Wherein ( ) is an optional ethylene bridge; R1 is alkyl, cycloalkyl, aryl or aryl substituted with one or more substituents selected from alkyl, alkoxy and amino, or R1 is pyridyl or pyridyl substituted with one or more substituents selected from alkyl, alkoxy and amino; R2 is optionally substituted alkyl, alkoxyalkyl, optionally substituted cycloalkylalkyl, arylalkyl, or R2 is arylalkyl substituted with one or more substituents selected from alkyl, alkoxy; X is -C(O)-, -C(O)-CH2-, -S(O)2-, or NH-C(O)- ; and A is optionally substituted alkyl or other substituents as defined in claim 1. Pharmaceutical compositions comprising such compounds, their preparation, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and/or tumor necrosis factor (TNF), such as asthma or joint inflammation.

  本发明提供了Formula (I)的化合物，其中( )是可选的乙烯桥；R1是烷基、环烷基、芳基或芳基，其上取代基可为烷基、烷氧基和氨基中的一种或多种，或者R1是吡啶基或吡啶基，其上取代基可为烷基、烷氧基和氨基中的一种或多种；R2是可选取代的烷基、烷氧基烷基、可选取代的环烷基烷基、芳基烷基，或者R2是芳基烷基，其上取代基可为烷基、烷氧基中的一种或多种；X是-C(O)-、-C(O)-CH2-、-S(O)2-或NH-C(O)-；A是可选取代的烷基或其他在权利要求1中定义的取代基。包括这些化合物的药物组合物、其制备以及在治疗能够通过抑制p38激酶和/或肿瘤坏死因子(TNF)调节的疾病状态中的药用，如哮喘或关节炎。
• Diaminothiazoles having antiproliferative activity
  申请人：——

  公开号：US20020151554A1

  公开（公告）日：2002-10-17

  Disclosed are novel diaminothiazoles that are selective inhibitors of Cdk4. These compounds and their pharmaceutically acceptable salts and esters are anti-proliferative agents useful in the treatment or control of solid tumors, in particular breast, colon, lung and prostate tumors. Also disclosed are pharmaceutical compositions containing these compounds as well as intermediates useful in the preparation of the compounds.

  揭示了一种新型的二氨基噻唑，它们是Cdk4的选择性抑制剂。这些化合物及其药学上可接受的盐和酯是抗增殖剂，在治疗或控制实体肿瘤，特别是乳腺、结肠、肺和前列腺肿瘤方面非常有用。还公开了含有这些化合物的药物组合物，以及制备这些化合物的中间体。
• Electrochemical diselenylation of indolizines <i>via</i> intermolecular C–Se formation with 2-methylpyridines, α-bromoketones and diselenides
  作者：Junxuan Li、Xiang Liu、Jiadi Deng、Yingshan Huang、Zihao Pan、Yue Yu、Hua Cao

  DOI：10.1039/c9cc08784b

  日期：——

  Diselenylated indolizines were achieved via intermolecular C–Se formation reaction between 2-methylpyridines, α-bromoketones and diselenides under undivided electrolytic conditions.

  通过无隔膜电解条件下2-甲基吡啶、α-溴酮和二硒代物之间的分子间C-Se形成反应实现了去硒基吲哚啉。
• Intermediates useful in the preparation of diaminothiazoles
  申请人：——

  公开号：US20040082595A1

  公开（公告）日：2004-04-29

  Disclosed are novel diaminothiazoles that are selective inhibitors of Cdk4. These compounds and their pharmaceutically acceptable salts and esters are anti-proliferative agents useful in the treatment or control of solid tumors, in particular breast, colon, lung and prostate tumors. Also disclosed are pharmaceutical compositions containing these compounds as well as intermediates useful in the preparation of the compounds.

  本发明涉及新型二氨基噻唑，它们是Cdk4的选择性抑制剂。这些化合物及其药学上可接受的盐和酯是抗增殖剂，可用于治疗或控制实体肿瘤，特别是乳腺、结肠、肺和前列腺肿瘤。还公开了包含这些化合物的药物组合物以及用于制备这些化合物的中间体。